Analyst Consensus ?
ConsensusBuy39 ratings
Bullish3179.5%
Neutral717.9%
Bearish12.6%
1 unmapped firm rating excluded from the percentages.
Agilent Technologies, Inc. · A · FY2026 Q2 · Calendar Q2 2026
Agilent Q2 FY26: Revenue and EPS Beat, Guidance Raised on Ignite-Driven Margins
Agilent's Q2 FY26 results reflect broad-based strength driven by the Ignite operating system's pricing and productivity initiatives, instrument replacement cycles, and share gains across multiple end markets. Revenue of $1.83 billion grew 6.3% on a core basis with operating margin expansion of 130 bps to 26.4%, translating to EPS of $1.49. The raised full-year outlook signals management confidence in sustained operational improvements, though geopolitical headwinds and China demand variability warrant monitoring.
Reported After market closeNYSEHealthcare
$39.63B market cap
90quality score
Company context
Snapshot as of publicationAgilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers.…
Earnings scorecard
Reported versus consensus
Reported EPS
$1.49
Consensus $1
EPS surprise
+5.7%
Reported versus consensus
Reported revenue
$1.83B
Consensus $1.80B
Revenue surprise
+2.0%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$140.3Current
$120Low
$156.1Average
$180High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jun 24, 2026 |
| Piper Sandler | Neutral | Overweight | Downgrade | Jun 11, 2026 |
| HSBC | Buy | Buy | Maintain | Jun 3, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jun 2, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 28, 2026 |
| TD Cowen | Buy | Buy | Maintain | May 28, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | May 28, 2026 |
| Baird | Outperform | Outperform | Maintain | May 26, 2026 |
| Keybanc | Sector Weight | Maintain | Apr 28, 2026 | |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 3, 2026 |
| UBS | Buy | Buy | Maintain | Feb 26, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Nov 25, 2025 |
| Citigroup | Buy | Buy | Maintain | Nov 25, 2025 |
| Jefferies | Hold | Hold | Maintain | Apr 21, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | Apr 16, 2025 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jun 27, 2024 |
| Stifel | Buy | Buy | Maintain | May 30, 2024 |
| Oppenheimer | Outperform | Outperform | Maintain | Mar 26, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Dec 7, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 16, 2023 |
| SVB Securities | Outperform | Outperform | Maintain | May 31, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 6, 2023 |
| CFRA | Buy | Buy | Maintain | May 26, 2022 |
| Cowen & Co. | Outperform | Outperform | Maintain | Sep 17, 2021 |
| Cleveland Research | Buy | Neutral | Upgrade | Nov 17, 2020 |
| Needham | Hold | Buy | Downgrade | Feb 24, 2020 |
| Stifel Nicolaus | Hold | Hold | Maintain | Nov 15, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Jul 16, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Jun 11, 2019 |
| Deutsche Bank | Buy | Buy | Maintain | May 15, 2019 |
| BTIG Research | Buy | Buy | Maintain | Aug 18, 2016 |
| BTIG | Buy | Buy | Maintain | Aug 18, 2016 |
| Janney Capital | Buy | Neutral | Upgrade | Sep 19, 2013 |
| ISI Group | Strong Buy | Buy | Upgrade | Sep 19, 2013 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Sep 18, 2013 |
| Longbow Research | Buy | Buy | Maintain | Aug 15, 2013 |
| Leerink Swann | Outperform | Outperform | Maintain | Mar 6, 2013 |
| S&P Capital IQ | Sell | Hold | Downgrade | Feb 15, 2013 |
| CLSA | Outperform | Buy | Maintain | Jan 17, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $140.3. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Vijay Kumar | $148 | $128.34 | +5.5% | Jul 6, 2026 |
| Piper Sandler | David Westenberg | $150 | $131.62 | +6.9% | Jun 11, 2026 |
| HSBC | Sidharth Sahoo | $165 | $135.04 | +17.6% | Jun 3, 2026 |
| RBC Capital | Analyst unavailable | $155 | $133.5 | +10.5% | May 28, 2026 |
| Robert W. Baird | Analyst unavailable | $158 | $115.83 | +12.6% | May 28, 2026 |
| Wells Fargo | Brandon Couillard | $160 | $115.83 | +14.0% | May 28, 2026 |
| RBC Capital | Dan Leonard | $153 | $115.08 | +9.1% | May 26, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $156 | $114.96 | +11.2% | May 26, 2026 |
| Barclays | Luke Sergott | $140 | $117.52 | -0.2% | Apr 14, 2026 |
| Fermium Research | Analyst unavailable | $150 | $114.21 | +6.9% | Mar 9, 2026 |
| HSBC | Analyst unavailable | $180 | $139.64 | +28.3% | Jan 20, 2026 |
| Evercore ISI | Analyst unavailable | $160 | $137.95 | +14.0% | Jan 5, 2026 |
| Goldman Sachs | Analyst unavailable | $170 | $142.44 | +21.2% | Dec 9, 2025 |
| Morgan Stanley | Analyst unavailable | $180 | $148.81 | +28.3% | Dec 2, 2025 |
| Morgan Stanley | Analyst unavailable | $270 | $150.1 | +92.4% | Dec 1, 2025 |
| Stifel Nicolaus | Daniel Arias | $170 | $158.22 | +21.2% | Nov 25, 2025 |
| UBS | Analyst unavailable | $180 | $153.6 | +28.3% | Nov 25, 2025 |
| Robert W. Baird | Catherine Ramsey Schulte | $165 | $153.6 | +17.6% | Nov 25, 2025 |
| Barclays | Analyst unavailable | $165 | $153.6 | +17.6% | Nov 25, 2025 |
| Wells Fargo | Analyst unavailable | $165 | $153.6 | +17.6% | Nov 25, 2025 |
| Redburn Partners | Analyst unavailable | $165 | $138.56 | +17.6% | Oct 8, 2025 |
| Jefferies | Analyst unavailable | $130 | $142.31 | -7.3% | Oct 3, 2025 |
| Barclays | Analyst unavailable | $150 | $138.58 | +6.9% | Oct 2, 2025 |
| Robert W. Baird | Analyst unavailable | $142 | $123.32 | +1.2% | Aug 28, 2025 |
| Wells Fargo | Brandon Couillard | $140 | $122.92 | -0.2% | Aug 28, 2025 |
| Jefferies | Analyst unavailable | $116 | $100.26 | -17.3% | Apr 21, 2025 |
| Barclays | Luke Sergott | $145 | $144.25 | +3.3% | Oct 15, 2024 |
| Citigroup | Patrick Donnelly | $165 | $143.82 | +17.6% | Oct 14, 2024 |
| Evercore ISI | Vijay Kumar | $145 | $148.48 | +3.3% | Oct 1, 2024 |
| Bank of America Securities | Michael Ryskin | $147 | $139.99 | +4.8% | Aug 22, 2024 |
| Jefferies | Brandon Couillard | $135 | $133.42 | -3.8% | Jul 22, 2024 |
| Stifel Nicolaus | Daniel Arias | $151 | $133.57 | +7.6% | May 30, 2024 |
| Robert W. Baird | Catherine Schulte | $136 | $145.48 | -3.1% | May 30, 2024 |
| Goldman Sachs | Matthew Sykes | $145 | $145.48 | +3.3% | May 30, 2024 |
| Stifel Nicolaus | Daniel Arias | $163 | $141.34 | +16.2% | Apr 4, 2024 |
| Evercore ISI | Ross Muken | $120 | $113.15 | -14.5% | Nov 20, 2023 |
| Wells Fargo | Dan Leonard | $170 | $153.44 | +21.2% | Jan 10, 2023 |
| Leerink Partners | Analyst unavailable | $170 | $145.3 | +21.2% | Jan 6, 2023 |
| UBS | Analyst unavailable | $170 | $147.67 | +21.2% | Dec 20, 2022 |
| Leerink Partners | Puneet Souda | $165 | $155.32 | +17.6% | Nov 22, 2022 |
| Robert W. Baird | Catherine Schulte | $161 | $120.38 | +14.8% | May 25, 2022 |
| Wells Fargo | Timothy Daley | $130 | $122.19 | -7.3% | Apr 29, 2022 |
Track every rating change on A the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
+16.9%
Event window
SPY move
+0.6%
Same window
Abnormal move
+16.3%
Stock minus SPY
Volume
2.9×
Versus trailing sessions
Subsequent drift
+0.5%
Up to 20 sessions
ASPY benchmark
Follow A with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Q2 FY26 exceeded guidance on revenue, margin, and EPS. Core revenue grew 6.3%, operating margin expanded 130 bps year-over-year to 26.4%, and EPS reached $1.49, a 14% increase. The beat was driven by Ignite-driven strategic pricing and operational efficiencies, robust instrument replacement cycles, and share gains. Full-year guidance was raised across revenue (core growth 4.5%-6.0%), EPS ($6.00-$6.10), and operating margin (+85 bps). New product launches announced include Infinity III LC, the 9.5k triple-quad ICPMS, and upgraded flagship GCs. The pending Biocare acquisition was positioned to broaden the antibody and clinical services portfolio. The stock reacted sharply, gaining approximately 16.9% the session after the report on 2.87x baseline volume.
Guidance delta
Full-year FY26 guidance was raised. Revenue core growth guidance set at 4.5%-6.0%, EPS guidance at $6.00-$6.10, and operating margin expansion guided to approximately +85 bps. Guidance sentiment is raised. Prior quarter comparison data was not available in the supplied source materials.
Key takeaways
- Q2 performance exceeded guidance on revenue, margin and EPS thanks to Ignite-driven pricing and operational efficiencies.
- Full-year outlook upgraded: revenue growth 4.5%-6.0% (core), EPS $6.00-$6.10, and additional margin expansion.
- Strong growth in CAM, diagnostics, forensics and spectroscopy, supported by new product launches and replacement-cycle tailwinds.
- Biocare acquisition positioned to broaden the antibody and clinical services offering.
- AI, digital commerce and supply-chain innovations are enhancing resilience and margin potential.
Management priorities
- Launch of Infinity III LC, new Altura columns and 9.5k triple-quad ICPMS at ASMS.
- Roll-out of upgraded flagship GCs with faster oven cool-down and helium-saving features.
- Opening of a China Innovation Center focusing on AI, digital, and automation.
- Integration of Biocare post-close and expansion of antibody menu.
- Continued investment in AI-enabled supply-chain and automation capabilities.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-28T01:17:19.619166+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T05:31:33.292807+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T05:31:33.290691+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.